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Abstract
Background: Influenza pandemic outbreaks occurred in the US in 1918, 1957, and 1968. Historical evidence
suggests that the majority of influenza-related deaths during the 1918 US pandemic were attributable to bacterial
pneumococcal infections. The 2009 novel influenza A (H1N1) outbreak highlights the importance of interventions
that may mitigate the impact of a pandemic.
Methods: A decision-analytic model was constructed to evaluate the impact of 7-valent pneumococcal conjugate
vaccine (PCV7) on pneumococcal disease incidence and mortality during a typical influenza season (13/100) and a
severe influenza pandemic (30/100). Outcomes were compared for current PCV7 vaccination practices vs. no
vaccination. The model was estimated using published sources and includes indirect (herd) protection of non-
vaccinated persons.
Results: The model predicts that PCV7 vaccination in the US is cost saving for a normal influenza season, reducing
pneumococcal-related costs by $1.6 billion. In a severe influenza pandemic, vaccination would save $7.3 billion in
costs and prevent 512,000 cases of IPD, 719,000 cases of pneumonia, 62,000 IPD deaths, and 47,000 pneumonia
deaths; 84% of deaths are prevented due to indirect (herd) protection in the unvaccinated.
Conclusions: PCV7 vaccination is highly effective and cost saving in both normal and severe pandemic influenza
seasons. Current infant vaccination practices may prevent >1 million pneumococcal-related deaths in a severe
influenza pandemic, primarily due to herd protection.
Background
Pandemic influenza outbreaks occurred in the US in
1918, 1957, and 1968, and the World Health Organiza-
tion declared the novel influenza A (H1N1) virus a pan-
demic in June 2009. The most notable pandemic
occurred in 1918 (H1N1 strain) and caused at least 20
million deaths worldwide, with some estimates as high
as 100 million [1-4]. Infection rates (25 - 50% of the
population) and deaths (up to 2%) were much higher
than is typically observed in an influenza outbreak [5].
A severe influenza pandemic similar to 1918 would have
devastating effects in the US and globally, with an esti-
mated 90 million cases of influenza, 1.9 million deaths,
9.9 million hospitalizations, 42 million outpatient visits,
and costs of up to $255 billion in the US alone [6].
The unprecedented severity of the 1918 influenza pan-
demic has led to much research, particularly on the high
burden of mortality in otherwise healthy young adults.
Experts agree that influenza alone cannot explain the
extraordinary number of pandemic deaths, but attach
different emphasis to the role of secondary bacterial
pneumonias. More recent studies support the conclu-
sions of investigators at the time of the pandemic [7]
that most deaths were due to complications of bacterial
pneumonia. A study of autopsy samples from victims of
the 1918 pandemic found bacteria in all samples, point-
ing to bacterial pneumonia as the cause of death [8].
Further, an analysis of the time to death from * Correspondence: jaime.rubin@i3innovus.com
1i3 Innovus, 10 Cabot Road, Suite 304, Medford, MA 02155, USA
Rubin et al. BMC Infectious Diseases 2010, 10:14
http://www.biomedcentral.com/1471-2334/10/14
© 2010 Rubin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.pneumonia associated with influenza in 1918 shows
concordance with contemporary accounts of time to
death from pneumococcal pneumonia [9]. A recent
autopsy study of H1N1 victims found bacterial pneumo-
nia in 55% of their samples [10]. These observations are
further supported by a recent double-blind randomized
trial of pneumococcal conjugate vaccine in children not
vaccinated for influenza that demonstrated a 45% lower
incidence of hospitalization due to influenza-associated
pneumonia among those receiving the pneumococcal
vaccine [11].
In 2000, the 7-valent pneumococcal vaccine (PCV7;
Prevenar; Wyeth Pharmaceuticals, acquired by Pfizer in
October 2009) was approved for pediatric use and
recommended by the Centers for Disease Control and
Prevention (CDC) for children aged up to 59 months
[12]. Routine infant vaccination with PCV7 (adminis-
t e r e da t2 ,4 ,6 ,a n d1 2t o1 5m o n t h so fa g e )[ 1 3 ]h a s
markedly decreased the incidence of invasive pneumo-
coccal disease (IPD) in both the vaccinated and general
populations [14-16]. CDC analyses from 2005 indicate
that most IPD (69%) was prevented through indirect
(herd) effects of the vaccine [17], likely due to decreased
nasopharyngeal carriage of pneumococcal strains among
immunized children, resulting in decreased transmission
to non-immunized children and adults [17]. The impact
of PCV7 on pneumococcal disease - including pneumo-
nia [18] and IPD [19] - in the unvaccinated population,
and the likely synergies between pneumococcal disease
and influenza, suggest current PCV7 vaccination prac-
tices may reduce morbidity and mortality in an influ-
enza pandemic. While influenza vaccination remains the
most effective means of reducing influenza-related mor-
bidity and mortality, the risk of influenza and pneumo-
coccal disease co-infectioni nap a n d e m i c ,a l o n gw i t h
the ability to vaccinate individuals prior to the onset of
a pandemic, provide strong rationale for considering
pneumococcal vaccination in the context of influenza.
This study examines the public health and economic
impact of current pneumococcal vaccination policies in
the context of the annual influenza epidemic and a
severe influenza pandemic.
Methods
Overview
We used a decision-analytic model of pneumococcal
disease incidence and outcomes to assess the impact of
current US pneumococcal vaccination practices on
pneumococcal disease burden during both an annual
influenza epidemic and a severe influenza pandemic,
relative to the hypotheticalb u r d e ni fn op n e u m o c o c c a l
immunization program had been implemented. The
model considers outcomes of pneumococcal disease
only; morbidity, mortality and costs of influenza without
pneumococcal co-infection are not considered. Out-
comes include cases of pneumococcal disease, pneumo-
coccal-related deaths, costs, survival (in life-years [LYs])
and quality-adjusted survival (in quality-adjusted life-
years [QALYs]). To simulate a single influenza season,
epidemiologic outcomes were calculated over a 1-year
period; incremental costs, survival, and quality-adjusted
survival reflect lifetime consequences of events occur-
ring during this 1-year period. Future costs and health
outcomes were discounted to present values using a 3%
annual discount rate [20]. This analysis presents results
from a payer perspective and all costs are in 2006
dollars.
Model Structure
Figure 1 shows clinical events relating to vaccination
and influenza incidence and treatment; the model popu-
lation is stratified into six age groups: 0 to <2 years, 2 to
4 years, 5 to 17 years, 18 to 49 years, 50 to 64 years, and
>65 years. Subsequent branching of the tree highlights
potential health outcomes of pneumococcal disease and
the possibility of developing meningitis, bacteremia,
pneumonia, or acute otitis media (AOM). Consistent
with other economic models [21,22] and the Northern
California Kaiser Permanente (NCKP) trial [23], menin-
gitis and bacteremia are defined as those caused by S.
pneumoniae, whereas pneumonia and AOM cases are
caused by any organism (all-cause). For simplicity, the
clinical manifestations of pneumococcal disease are
modeled as mutually exclusive, with risk of occurrence
following a hierarchy of severity from most severe to
least severe: meningitis, bacteremia, pneumonia, AOM.
Model Estimation
Input parameters used in the model and corresponding
data sources are presented in Table 1.
Population, Vaccine Coverage, Incidence & Mortality
The age group distribution of the US population was
estimated from the 2006 US Census [24]. Current vacci-
nation practices are defined based on 2006 data from
the National Immunization Survey (NIS) as 87% of chil-
dren <2 years vaccinated with PCV7; 79% of these chil-
dren receive 4 doses, and the remainder 3 doses. We
assumed that children aged 2 to 4 years were vaccinated
an average of 2 years prior to the start of the model,
therefore, NIS data from 2004 were used to estimate the
proportion of children in this age group who retained
vaccine protection (69% of those receiving 3 or more
doses and 71% of those receiving 4 doses) [25]. Age-spe-
cific disease incidence rates before PCV7, case-fatality
rates, and complication probabilities for pneumococcal
disease manifestations were estimated from published
sources [14,15,21,22,26-31].
Vaccine Efficacy & Indirect (Herd) Effects
Vaccine effectiveness (efficacy and indirect [herd] effects)
estimates in all age groups are shown in Table 1. Vaccine
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based on results of the NCKP trial. In vaccinated children
<2 years, vaccination was assumed to directly reduce the
probability of pneumococcal infection by the recorded effi-
cacy of the vaccine [23] for children 2 - 4 years; efficacy
was reduced to reflect waning effectiveness of the vaccine
over time [22]. Indirect (herd) effects were incorporated in
the model as a percent reduction in disease incidence. To
calculate herd effects on IPD in the vaccine-eligible popu-
lation, we used differences in the observed changes in dis-
ease incidence from the Center for Disease Control and
Prevention’s Active Bacterial Core Surveillance (ABCs)
Report and direct vaccine efficacy from the NCKP trial,
assuming all changes in incidence not attributable to vac-
cine efficacy were attributable to indirect (herd) effects
[14,15,23].
Ecologic data on pneumonia-related hospital admis-
s i o n sa n dA O Mv i s i t ss u g g e s t st h a tP C V 7v a c c i n a t i o n
may have led to larger reductions in all-cause pneumo-
nia (39.0%) and AOM (42.7%) in children than trial effi-
cacy data indicate [18,23,32]. We therefore estimated
the effectiveness (both direct and indirect) of vaccina-
tion in children as the midpoint between the NCKP trial
estimates and the ecologic data [32-34]. We then calcu-
lated the indirect (herd) effect of vaccination assuming
all changes in incidence not attributable to direct pro-
tection were attributable to indirect (herd) protection
and that indirect (herd) effects apply to both the vacci-
nated and unvaccinated populations.
Indirect (herd) effects in the unvaccinated age groups
were calculated from observed reductions in IPD inci-
dence [14,15] before and after the introduction of PCV7
[21]; all reductions in disease were assumed to occur in
the 7 serotypes included in the vaccine. Because it is not
known what proportion of the observed reduction in
pneumonia is attributable to the vaccine, and regional
analyses have not supported changes observed in
national datasets [26,35], we assumed that effects in the
unvaccinated were equal to 50% of the estimated effect
reported by Grijalva et al. [18].
Influenza
One-year cumulative influenza incidence was calculated
from the CDC’s Flu Activity & Surveillance Weekly
Activity Reports (13%) [36,37]. It was assumed that per-
sons with influenza were at a higher risk of pneumococ-
cal disease than those without influenza. Persons
without influenza were considered the reference group
and those with influenza were assumed to have 7.7%
increased risk of pneumococcal disease; the increased
r i s kw a sc a l c u l a t e df r o mas t u d yt h a te x a m i n e de x c e s s
pneumococcal infections during a normal influenza sea-
son (RR: 1.077) [38]. Base-case probabilities of pneumo-
coccal disease were adjusted to reflect the non-
pandemic relative risk for persons with versus without
influenza; therefore overall rates of disease in a non-
pandemic year are equal to incidence rates from the lit-
erature. We assumed that persons treated for influenza
were at 26.3% lower risk of pneumococcal disease
Figure 1 Decision model structure. In each age group, persons could be vaccinated or unvaccinated, depending on vaccination policy and
coverage (node 2). Both vaccinated and unvaccinated persons are at risk of influenza (node 3) and may or may not receive treatment for this
condition (node 4). Pneumococcal disease sub tree. In the model, persons are first subject to the risk of meningitis (node 5), which can lead to
death (node 6) or to deafness, disability, or no sequelae (node 7). Those not experiencing meningitis are subject to the risk of bacteremia (node
8), including bacteremic pneumonia, which may lead to death (node 9). Similarly, persons who do not contract meningitis or bacteremia are
then at risk for non-bacteremic pneumonia (node 10) and AOM (node 11), and they can die of pneumonia (nodes 12). Persons may also die of
causes unrelated to pneumococcal disease; these deaths are incorporated into the event-specific mortality probabilities (at nodes 6, 9, 12, and
14), and are captured separately for those who avoid acute pneumococcal events (node 13).
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Age group (years)
0 - <2 2 - 4 5 - 17 18 - 49 50 - 64 65+
Annual Incidence per 100,000
Pneumococcal meningitis
/a 9.1 1.1 2.3 0.5 1.5 1.7
Pneumococcal bacteremia
/a 174.8 35.8 3.8 12.3 22.7 58.8
All-cause pneumonia
/b 4,710 1,517 329 383 1,462 9,294
All-cause otitis media (per person)
/c 1.10 0.58
Case Fatality Rates
Pneumococcal meningitis
/d 0.05 0.05 0.04 0.13 0.21 0.27
Pneumococcal bacteremia
/d 0.01 0.01 0.02 0.08 0.12 0.16
All-cause pneumonia
/e 0.00 0.02 0.02 0.02 0.05 0.05
Proportion meningitis cases resulting in (%)
Deafness
/f 13.0 13.0 6.4 13.0 13.0 13.0
Disability
/f 6.7 6.7 5.2 6.7 6.7 6.7
Vaccine Effectiveness
IPD
Efficacy
/g 73.5% 67.0%
Indirect (herd) effect
/h 46.8% 40.3% 17.5% 38.3% 17.4% 33.6%
All-cause pneumonia
Efficacy
/i 6.9% 6.3%
Indirect (herd) effect
/j 17.6% 18.9% 9.0% 13.0% 9.3% 7.7%
All-cause otitis media
Efficacy
/i 6.4% 5.8%
Indirect (herd) effect
/k 20.1% 19.0%
Costs ($) per Case of Pneumococcal Disease
Meningitis
/l 13,196 13,196 7,446 10,586 13,461 10,263
Deafness
/m 101,975 101,387 97,679 82,278 57,428 31,733
Disability
/m 526,174 523,143 504,006 424,543 296,317 163,738
Bacteremia
/l 2,754 2,754 7,446 10,586 13,461 10,263
Pneumonia
/n 592 592 5,166 6,465 7,558 7,263
Otitis media
/o 256 256
Indirect (herd) effect refers to percent reduction in disease incidence in the unvaccinated
IPD = invasive pneumococcal disease
a. Incidence of pneumococcal meningitis and bacteremia were estimated from the published ABCs report [15]. The ABCs reports incidence for 18-34 and 35-49
year old persons separately; we combined these age groups using weighted averages based on census data.
b. Incidence rates for all-cause pneumonia were adapted from Ray et al., which used unpublished Kaiser Permanente data to estimate incidence in unvaccinated
populations [2126].
c. Incidence of AOM adapted from Ray et al., combining simple and complex AOM. Only children <5 years were assumed to be at risk for AOM [21].
d. Case-fatality rates for IPD were estimated from the published ABCs report [1415] and Robinson et al. [33]; we divided the incidence reported in the ABCs by
the age-specific mortality reported by Robinson et al.
e. Case-fatality rates for pneumonia were estimated from a study of community-acquired pneumonia [31]. It was assumed that there was no risk of death from
AOM.
f. The probabilities of deafness and disability due to meningitis were adapted from data in children and adolescents with bacterial meningitis [22272829].
g. Adapted from the NCKP trial of PCV7 [23]; 94% (intent-to-treat) efficacy against covered serotypes, with PCV7 coverage of approximately 80% against S.
pneumoniae serotypes that cause pneumococcal meningitis and bacteremia.
h. In children <5 estimated as the difference between observed changes in disease incidence from the (ABCs) Report and direct vaccine efficacy from the NCKP
trial, assuming all changes in incidence not attributable to vaccine efficacy were attributable to indirect (herd) effects [141523]; in adults estimated based
changes in incidence reported in the ABCs report.
i. Based on intent-to-treat data from the NCKP trial for PCV7 [23].
j. In children < 5, estimated from assuming overall effectiveness is the midpoint between the NCKP trial data, which reported vaccine efficacy of 6.9% in all-cause
pneumonia [26] and ecologic data reported by Grijalva (39% reduction) [18] and assuming all reductions in disease not attributable to vaccine efficacy are
attributable to indirect (herd) effects. We chose the midpoint because it is not known what proportion of the reduction in admissions reported by Grijalva were
due to the direct effects of PCV7 versus indirect (herd) effects within the vaccine-eligible population, and these ecological data reflect changes in hospital
admissions for pneumonia rather than incidence; final estimates of indirect (herd) effects against pneumonia were similar in magnitude to the reduction in x-ray
confirmed pneumonia from the trial [3334]. In adults, indirect (herd) effects against pneumonia were estimated from ecologic data reported by Grijalva et al.
[18].
k. Efficacy against AOM was calculated in a manner similar to that of pneumonia; we used the midpoint between the NCKP trial estimate (6.4%) [23] and results
from a study that examined changes in AOM-related outpatient visits before and after the introduction of PCV7 (42.7% reduction) [32]; our assumption of the
estimated proportion of the reduction in AOM cases that is biologically plausible to be attributable to PCV7 was based on expert opinion (personal
communication with Keith Klugman, MD, PHD, Steve Pelton, MD, and Michael E. Pichichero, MD).
l. The cost of diagnosing and treating meningitis and bacteremia, were derived from Ray et al. [2122]. Because this study did not report costs of meningitis and
bacteremia separately for persons >5 years of age, we assigned the reported cost to both meningitis and bacteremia in these age groups.
m. Costs of long-term consequences of meningitis were adapted from lifetime costs of deafness and disability for children <5 years [21]. To calculate the lifetime
costs in persons aged >5 years, we multiplied the costs for children <5 years by the proportional difference in discounted life-expectancy as estimated from US
life-tables [45].
n. We combined costs of hospitalized pneumonia for persons >5 years of age [21] and non-hospitalized community-acquired pneumonia [45] to calculate the
overall cost of all-cause pneumonia, assuming hospitalization rates of 12% for those aged 5 to 17 years, 28% for 18- to 49-year-olds, 25% for those aged >50
[182147].
o. We assumed that 7% of AOM cases are complex and 1.4% of cases required tympanostomy tube placement [22], and estimated the cost of simple AOM as
$192, complex AOM as $557, and tympanostomy tube placement as $2,687 [21]. The reported cost is a weighted average of simple and complex AOM and cases
requiring tube placement.
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duration of influenza from a trial of oseltamivir versus
placebo [39,40]. The proportion treated for influenza
was estimated from published sources examining treat-
ment patterns for influenza [41-44].
Costs & Utilities
All costs were estimated from published sources and
converted to 2006 US dollars using the Consumer Price
Index [18,21,22,45-49]. The average price for a single
dose of PCV7 was assumed to be $66.50 [48] with an
administration cost of $9.92 [21]. To account for the 5-
year benefit of vaccination, we amortized the cost over a
5-year period, discounting all future years by 3%. Utility
values, measures of quality-of-life ranging from 0 to 1
used to calculate QALYs, were adapted from a cost-
effectiveness analysis of pneumococcal vaccination [50].
Utilities associated with acute disease states were incor-
porated into the model by assigning a “toll” in the form
of an absolute QALY decrement to each episode of ill-
ness. We applied a decrement of 0.023 for meningitis,
0.008 for bacteremic pneumonia, 0.006 for hospitalized
pneumonia, 0.004 for non-hospitalized pneumonia, and
0.005 for AOM to all age groups. Utilities for chronic
states (deafness and disability) were estimated from ret-
rospective studies of meningococcal complications as
0.73 for deafness and 0.68 for disability [51,52] and
applied to the remaining life expectancy.
Pandemic Calibration
To test the assumption that synergies between influenza
and pneumococcal disease observed during a normal
influenza season are magnified during a pandemic
[53-55], we increased the incidence of influenza in our
model to 30%, which is consistent with expected inci-
dence of influenza in a pandemic in the US [2]. How-
ever, we were unable to replicate the increased
incidence of pneumococcal disease seen during the 1918
pandemic. To estimate the effect of influenza on pneu-
mococcal disease incidence during a severe pandemic,
we calibrated the increased relative risk of pneumonia
(bacteremic and non-bacteremic) for those with influ-
enza versus those without to achieve the 5% incidence
of combined infection with influenza and pneumonia
observed in 1918 [56]. To estimate age-specific influenza
and pneumonia incidence, we applied estimates of age-
specific excess population mortality in 13 countries, and
scaled the pneumonia and influenza incidence in pro-
portion to the observed excess pneumococcal and influ-
enza-related mortality in the US (0.39%), assuming 30%
of persons had influenza [57]. When performing the
calibration, we also assumed that 30% of pneumonia
cases were bacteremic in a severe pandemic [55]. The
largest increase in incidence was observed among influ-
enza cases in the 18 - 49 year age group (4-fold). Due to
the introduction of antibiotics, it was deemed unlikely
that the next pandemic would result in the excess mor-
tality of 0.39% seen in the US during the 1918 pan-
demic. We assumed that case-fatality rates for IPD and
pneumonia during a severe pandemic would instead be
similar to those of persons on antibiotic therapy (10%
for all-cause pneumonia in all age groups and 10% for
IPD for those <50 years) [58]. The case-fatality for those
>50 years was assumed to be equal to the case-fatality
rates in a normal influenza season.
Analyses
Base-case Analyses
Base-case analyses assumed a population of 300 million
people. It was assumed that 7.2 million infants (<2 years
of age) were fully vaccinated at the start of the model,
and that 8.5 million children 2 - 4 years of age had been
vaccinated prior to the start of the model and were still
receiving immunological benefits. Unvaccinated persons
benefited from vaccination via indirect (herd) effects.
The model was used to calculate cases of pneumococcal
disease avoided, deaths averted, QALYs gained, LYs
saved, and costs. Cases avoided and deaths averted were
calculated as the difference in the total number of
cases/deaths under a policy of no vaccination minus the
total number of cases/deaths under current vaccination
practices. Total costs with vaccination were calculated
as the cost of vaccination less any cost offsets associated
with avoiding disease.
Incremental cost-effectiveness ratios (ICERs) were
estimated in terms of additional cost per QALY gained
or additional cost per LY saved, and calculated by divid-
ing the difference in costs by the difference in QALYs
or LYs. LYs saved for each death averted were calcu-
lated using the discounted l i f ee x p e c t a n c ya te a c ha g e .
QALYs gained were calculated based on LYs saved, first
converting discounted life expectancy at each age into
quality-adjusted life expectancy, then weighting each
discounted year of life by an age-specific utility weight
for healthy individuals [59]. Lifetime consequences of
meningitis were included by assigning the utility asso-
ciated with meningitis sequelae for the duration of age-
specific discounted life-expectancy and subtracting the
resulting quality-adjusted life-expectancy from the qual-
ity-adjusted life-expectancy without meningitis sequelae.
Finally, to account for acute illness disutility, QALY
decrements were subtracted from quality-adjusted life-
expectancy. All costs and life years were discounted at
3% per annum. Analyses were conducted under condi-
tions of a normal influenza season (influenza incidence
of 13%) and a severe pandemic season (influenza inci-
dence of 30%).
Sensitivity Analyses
Because the pneumonia and influenza incidence distribu-
tion of a future pandemic is uncertain, we re-calibrated
the pandemic parameters to reflect the current age
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tion target remained at 5% incidence of combined pneu-
monia and influenza; however, we re-distributed the
burden such that persons >65 years and <2 years had the
highest incidence of pneumococcal disease and those aged
5 - 49 years the lowest. Case-fatality rates remained
unchanged from the base-case pandemic analysis.
A series of one-way sensitivity analyses were per-
formed to assess the robustness of model results to
plausible alternative assumptions regarding input para-
meters. The proportion of the observed reduction in
pneumonia post-introduction of PCV7 that is attributa-
ble to PCV7 is uncertain; we varied the indirect (herd)
effect on pneumonia from zero to the values reported
by Grijalva et al. [18]. Because treatment patterns for
influenza may change during a pandemic, we varied the
percent of persons treated for influenza by ± 25%. To
reflect the uncertainty in the incidence and mortality
burden of a future pandemic, we re-estimated the model
assuming that bacteremic pneumonia incidence and
case-fatality were reduced by 50% from the base-case.
To account for the effect of possible antibiotic shortages
during a pandemic, case-fatality rates for bacteremic and
all-cause pneumonia were increased to 20 percent.
Other sensitivity analyses included: [1] reducing
assumed effectiveness of pneumococcal vaccination on
AOM to 6% (reported in the NCKP trial [23]) and
increasing effectiveness to the 42.7% reported by Zhou
et al. [32]; [2] varying price of the vaccine by ± 10%; [3]
varying incidence of invasive disease by ± 10%; and [4]
varying vaccine coverage rates by ± 10 percent. Sensitiv-
ity analyses are reported for pandemic conditions only.
Results
Non-pandemic influenza season
The model predicts that current vaccination practices
prevent approximately 32,300 IPD cases, 550,100 pneu-
monia cases, 2,200 IPD deaths, and 21,000 pneumonia
deaths during a normal influenza season. Cost savings
are estimated to be $1.57 billion; vaccination with PCV7
i sp r e d i c t e dt ob el e s sc o s t l ya sw e l la sm o r ee f f e c t i v e
than no PCV7 vaccination (i.e., dominant).
Severe pandemic season
Base-case
To reach the expected excess incidence of pneumococcal
disease during a severe pandemic, the relative risk of bac-
teremic pneumonia among persons with influenza versus
without influenza was increased by a multiple ranging
from 15-fold in children <2 years to 150-fold in persons
aged 5 - 17 years over the estimate for a non-pandemic
year. It was assumed that persons without influenza were
not at increased risk of pneumococcal disease during a
severe pandemic. Table 2 shows the calibrated incidence
of pneumococcal disease for persons with influenza
during a severe pandemic season; non-pandemic inci-
dence rates are included as a point of reference.
Projected outcomes during a severe pandemic are dis-
played in Table 3. The majority of cost savings are attri-
butable to avoiding disease in the non-vaccine-eligible
age groups. Preventing pneumococcal disease in persons
aged 18 - 49 or >65 years each accounts for 40% of the
cost savings and accounts for 80% combined. The
model predicts that pneumococcal vaccination would
lead to 2.0 million LYs saved by avoiding 109,000 deaths
due to IPD or pneumonia, and 2.1 million QALYs
gained, in a population of 300 million. The majority of
LYs saved and QALYs gained are in the 18 - 49 year
age group, where vaccination is expected to lead to
841,000 LYs saved and 784,000 QALYs gained in a
severe pandemic.
Sensitivity Analyses
In addition to the base-case estimates, table 3 shows the
sensitivity of pneumococcal disease cases, deaths, and
costs to variations in model inputs in a severe pandemic
influenza season. Redistributing the disease burden to
reflect current age distributions of disease incidence
results in fewer cases of IPD avoided due to less indirect
(herd) effect against bacteremic pneumonia in the elderly
when compared with younger adults (18 - 49 years).
Model results are sensitive to reductions in the inci-
dence and case-fatality rates of bacteremic pneumonia
and all-cause pneumonia, which lead to substantial
cases and deaths averted as well as cost savings. Assum-
ing additional herd protection against pneumonia at the
levels reported by Grijalva et al. [18] or additional vac-
cine effectiveness against AOM [32], substantially
increases cost savings. Assumed changes in vaccination
practices as well as small changes (± 10%) in the percen-
tage of persons receiving treatment for influenza, the
case-fatality from IPD or pneumonia, and the price of
the vaccine have minimal effects on model results.
Discussion
To our knowledge, no other studies have evaluated the
economic impact of vaccination with PCV7 during an
influenza pandemic. Studies have examined the cost-
effectiveness of PCV7 against pneumococcal disease
[21,22,50,60-63]. However, these studies did not exam-
ine PCV7 in the context of influenza. Results of our
study are consistent with studies examining other inter-
ventions to reduce the epidemiologic and economic
impact of an influenza pandemic. For example, studies
in Israel [64], Singapore [65] and the UK [66] found
stock-piling antiviral drugs to be either cost-effective or
cost saving in a pandemic. One study assessed vaccina-
tion with a 23-valent pneumococcal vaccine in the con-
text of an influenza pandemic in the Netherlands. The
study found that in the absence of an available influenza
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nation should be administered to the elderly and groups
at a high risk for influenza, in order to limit the number
of resulting hospitalizations and deaths [67].
Several conservative assumptions regarding the effects
of pneumococcal vaccination and disease epidemiology
were made. We assumed no direct protection against
pneumococcal disease after 5 years of age. While it is
unlikely that the vaccine will wane to zero when chil-
dren turn age 5, data are not available to characterize
the degree of waning vaccine efficacy in this age group
over time. We therefore made assumptions consistent
with previously published cost-effectiveness models of
PCV7 [21]. The pneumonia (bacteremic and non-bac-
teremic) case-fatality rate of 10% during a pandemic
assumes access to antibiotics would not be disrupted;
however, it is likely that access may be restricted due to
increased demand and subsequent shortages. We also
included conservative estimates of indirect (herd) effects
against AOM and pneumonia in the vaccine-eligible
population, taking the midpoint of observed vaccine effi-
cacy in the NCKP trial and the observed reductions in
hospital admissions from a community-based study
[18,26,32]. Even under these conservative assumptions,
the base-case outputs predict a large positive public
health and economic impact of vaccination.
Our study is subject to a number of limitations
inherent in the study design. First, the decision-analy-
tic model is necessarily a highly simplified representa-
tion of the disease transmission and outcomes of
pneumococcal disease. Although we accounted for
some differences in treatment and outcomes using age
stratification, we recognize that the US population and
health-care delivery system is highly heterogeneous
and may not be well represented by the relatively sim-
ple structure of this model. We also note that data
used to estimate vaccine effectiveness and outcomes
were derived and synthesized from a variety of sources,
and this process of interpretation and decision-making
is subject to bias. Although extensive sensitivity ana-
lyses to evaluate the effect of alternative parameter
choices on our outcomes showed no change in the
overall conclusions, we recognize that different
assumptions may have yielded different results. Costs
used in this analysis were taken from published data
and standard sources; the extent to which they reflect
the true costs of administering medical care is
unknown. Furthermore, this study was conducted from
a third-party payer perspective rather than a societal
perspective, and as such does not include costs of
pneumococcal disease related to lost productivity, care-
giver time, transportation, or other unreimbursed
expenses. Inclusion of indirect costs presumably would
have added substantially to the total cost burden of
pneumococcal disease and the potential cost savings
with PCV7. In addition, the model was estimated using
US data, and care should be used in generalizing our
results to other settings and populations.
Because the disease and mortality burden have dif-
fered both in magnitude and age distribution during the
four pandemics that have occurred in the past century,
it is difficult to characterize a “typical” pandemic. Our
assumptions derived from the 1918 pandemic likely
reflect a relatively severe influenza pandemic scenario.
Preliminary novel influenza A (H1N1) pandemic data
indicate that it is less virulent than previous pandemic
strains, with fewer required hospitalizations, and deaths
more likely to be concentrated in those with underlying
medical conditions [68]. There is also evidence that the
presence of secondary bacterial infections in persons
with influenza is lower in the 2009 pandemic relative to
the 1918 pandemic [10,69], indicating that the novel
H1N1 disease burden will likely fall between that of a
normal season and a severe pandemic. Because PCV7
vaccination is beneficial under both the severe pandemic
and seasonal epidemic scenario, we can infer that PCV7
would also result in cost savings and public health bene-
fits in a less severe pandemic. Future analyses assessing
the impact of pneumococcal vaccination in the context
of the novel influenza A (H1N1) pandemic will be
undertaken as more data become available.
We acknowledge that access to care and antibiotics,
as well as volume and means of travel have changed
dramatically since 1918. However, under various
Table 2 Incidence in pandemic and non-pandemic years
Age group (years)
Annual Incidence of
PD per 100,000
0-
<2
2-4 5-
17
18 -
49
50 -
64
65+
Incidence of PD in a non-pandemic year (13% influenza incidence)
Among persons
without influenza
Bacteremic
pneumonia
173.0 35.4 3.7 12.1 22.5 58.2
Other pneumonia 4,662 1,501 326 379 1,447 9,200
Among persons with
influenza
Bacteremic
pneumonia
186.3 38.1 4.0 13.1 24.2 62.6
Other pneumonia 5,020 1,616 351 408 1,558 9,906
Incidence of PD in a severe pandemic year (30% influenza incidence)
Among persons with
influenza
/a
Bacteremic
pneumonia
2,898 1,688 600 1,192 1,056 4,166
Other pneumonia 6,954 4,006 1,409 2,814 2,491 10,143
PD = pneumococcal disease
a. The incidence of PD among persons without influenza during a pandemic
is assumed to be the same as in a non-pandemic year
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Page 7 of 11assumptions meant to capture how access to care,
antibiotic use, and differences in disease transmission
may alter disease dynamics (i.e., reducing incidence
and mortality during a pandemic), pneumococcal vac-
cination still remains highly cost saving. We also
acknowledge that this 1-year model estimated from
2006 data includes the indirect (herd) effects of a
national immunization program with PCV7 that has
been established over 6 years, and only accounts for
the costs of vaccination of 4 birth cohorts (children
aged 1 year, 2 years, 3 years, and 4 years). In order to
quantify the current value of the ongoing vaccination
program, we chose to include the full effects of vacci-
nation. If we had accounted for the costs and benefits
over each year since the launch of PCV7, the economic
argument likely would be diminished, as the indirect
benefit grew over the 4 - 6 years after the launch of
the vaccine. However, even if we assume that only half
of the indirect benefit had accrued after 4 years of vac-
cination, the model predicts that vaccination would
avoid >700,000 cases of pneumonia and save >$3.5 bil-
lion in a severe influenza pandemic year.
We also note that the model includes neither the cost
nor potential benefits of influenza vaccination at the
onset of a pandemic. Assumed pandemic-level rates of
influenza in the model are consistent with no vaccina-
tion or a vaccine miss-match. If, however, we assume
the influenza vaccine is well matched (80% efficacy)
with coverage equal to that reported in 2006 [70], severe
pandemic incidence would decline from 30% to 24
Table 3 Base-case and sensitivity analysis results
Analysis Values Cases
avoided
Deaths
averted
Cost (savings) in billions of
$
Base-case – 4,726,000 108,500 (7.34)
Re-calibrated using current non-pandemic incidence distribution by
age
– 4,430,000 73,100 (4.8)
Incidence and case-fatality of bacteremic pneumonia - reduced by
50%
– 3,873,000 39,600 (4.09)
Case-fatality rates for IPD and pneumonia - increased to 20% – 201,000 (7.33)
Herd effect on pneumonia
Low (0%) 0% 4,106,000 59,600 (5.61)
High
16 15% - 26% 5,345,000 157,300 (9.07)
Incidence of IPD (per 100,000)
Low (-10%) 296 - 8,365 4,689,000 102,700 (6.77)
High (+10%) 383 - 10,224 4,763,000 114,200 (7.90)
Incidence of all-cause pneumonia (per 100,000)
Low (-10%) 5 - 165 4,681,000 103,700 (7.17)
High (+10%) 7 - 202 4,770,000 113,300 (7.50)
Vaccine effectiveness on AOM (<2 Yr)
Low
21 6% 2,687,000 – (6.81)
High
27 42% 10,444,000 – (8.80)
Vaccine coverage (<2)
Low (-10%) 78% 4,661,000 107,900 (7.40)
High (+10%) 96% 4,790,000 109,000 (7.27)
Price of vaccine
Low (-10%) $68.78 –– (7.44)
High (+10%) $84.06 –– (7.24)
Influenza treatment
Low (-10%) 8% - 16% 4,728,000 – (7.34)
High (+10%) 14% - 26% 4,725,000 – (7.34)
Case-fatality from IPD
Low (-10%) 0.8% - 25% – 102,400 –
High (+10%) 0.9% - 30% – 114,500 –
Case-fatality from all-cause pneumonia
Low (-10%) 0.4% - 4.7% – 103,700 –
High (+10%) 0.5% - 6% – 113,300 –
IPD = invasive pneumococcal disease; AOM = acute otitis media
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Page 8 of 11percent [71]. Under these conditions, the model predicts
that vaccination with PCV7 would result in 681,000
cases of pneumonia avoided (compared to 715,000 cases
in the base-case) and $6.2 billion in cost savings. Non-
pandemic model results are based on recent influenza
incidence data and reflect current rates of influenza
vaccination.
Finally, it is important to note that S. pneumoniae is
not the only pathogen known to complicate influenza
during a pandemic. In a recent autopsy study of 22
H1N1 victims with bacterial co-infection, 45% were co-
infected with S. pneumoniae, 32% were co-infected with
S. aureus, and 27% were co-infected with Group A
streptococcus (GAS). It is possible that S. aureus or
GAS could be the primary cause of bacterial co-infec-
tions in a future influenza pandemic, and S. pneumonaie
could play a less prominent role than in past pandemics.
In that case, the benefits of pneumococcal vaccination
would be less than those reported in this analysis. Vacci-
nation programs against other pathogens such as S. aur-
eus or GAS should be considered as other possibilities
for influenza pandemic preparedness.
Our model predicts that routine pneumococcal vac-
cination is a proactive approach to mitigate effects of a
future influenza pandemic, preventing numerous cases
of pneumococcal disease and averting >100,000 deaths.
The model also highlights the potential to save billions
of dollars in health-care costs during an influenza pan-
demic by avoiding cases of pneumococcal disease and
associated health-care utilization. This analysis details
additional potential public health and economic bene-
fits of universal vaccination with PCV7, which has
already been estimated to be highly cost-effective or
cost saving in many countries from various regions of
the world [50,62-64]. Countries that have not yet
implemented a pneumococcal vaccination program
may want to consider it as part of influenza pandemic
preparedness.
Conclusions
The biological plausibility of a link between influenza
and increased risk for subsequent pneumococcal dis-
ease rests on a number of biological responses to influ-
enza that increase susceptibility to pneumococcal
infection [72]. The timing of the exposure to the pneu-
mococcus in relation to the influenza appears to be
critical to the outcome in mice– there is no increased
mortality if the pneumococcal exposure precedes influ-
enza, an intermediate risk if exposure is concurrent,
and greatly increased risk for a pneumococcal exposure
7 days post-influenza [73]. The likely biological basis
for this observation is the effect of g-interferon, which
peaks in mice at 7 days post-influenza and inhibits the
ability of alveolar macrophages to clear the
pneumococcus [74]. Studies in humans suggest that
d e a t h sd u r i n gt h e1 9 1 8i n f l u e n z ap a n d e m i cw e r ed u e
to complications of bacterial pneumonia [7,8]. More-
over, recent research suggests that pneumococcal con-
jugate vaccine reduces influenza-associated pneumonia
hospitalizations [11].
Given the apparent link between pneumococcal dis-
ease and influenza, it is likely that vaccination with
PCV7 would reduce the public health burden during an
influenza pandemic. Our model predicts that current
pneumococcal vaccination practices would substantially
reduce the number of cases of all-cause pneumonia and
deaths during a severe influenza pandemic by approxi-
mately 719,000 and 47,000, respectively. The model also
predicts considerable cost savings associated with avoid-
ing pneumococcal disease episodes ($7.3 billion). A
large number of the cases avoided are attributable to
indirect (herd) effects in the unvaccinated; however,
even when indirect (herd) effects are reduced or elimi-
nated, the model still predicts a significant reduction in
pneumococcal-related costs during a pandemic.
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